Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13669)	10/1/2004 3:20:44 PM
From: VAUGHN	Respond to of 14101

Hello Cal Off the wire: yahoo.reuters.com Just a little back of the envelope crunching here and I don't know what DMX nets off the sale of a bottle of Pensaid, but the article says Merck had about 80m customers for Vioxx. If DMX only picked up 1% of those customers, that would appear to offer about $15m to $20m to DMX's bottom line or about $.17/s . Presuming say a P/E of 16 that suggests DMX shares could find there way back to about $2.80+/- in the forseeable future. Fingers crossed. Vaughn